- Home
- BNAI vs BIAF Comparison
BNAI vs BIAF Comparison
Compare BNAI & BIAF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BNAI
- BIAF
- Stock Information
- Founded
- BNAI 2018
- BIAF 2014
- Country
- BNAI United States
- BIAF United States
- Employees
- BNAI N/A
- BIAF N/A
- Industry
- BNAI
- BIAF Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- BNAI
- BIAF Health Care
- Exchange
- BNAI NYSE
- BIAF Nasdaq
- Market Cap
- BNAI 12.3M
- BIAF 12.2M
- IPO Year
- BNAI N/A
- BIAF 2022
- Fundamental
- Price
- BNAI $0.57
- BIAF $0.28
- Analyst Decision
- BNAI Strong Buy
- BIAF Hold
- Analyst Count
- BNAI 1
- BIAF 1
- Target Price
- BNAI $6.00
- BIAF N/A
- AVG Volume (30 Days)
- BNAI 19.1M
- BIAF 9.1M
- Earning Date
- BNAI 06-10-2025
- BIAF 05-15-2025
- Dividend Yield
- BNAI N/A
- BIAF N/A
- EPS Growth
- BNAI N/A
- BIAF N/A
- EPS
- BNAI N/A
- BIAF N/A
- Revenue
- BNAI $60,000.00
- BIAF $8,809,228.00
- Revenue This Year
- BNAI N/A
- BIAF N/A
- Revenue Next Year
- BNAI N/A
- BIAF $20.00
- P/E Ratio
- BNAI N/A
- BIAF N/A
- Revenue Growth
- BNAI N/A
- BIAF 78.40
- 52 Week Low
- BNAI $0.23
- BIAF $0.16
- 52 Week High
- BNAI $5.80
- BIAF $2.99
- Technical
- Relative Strength Index (RSI)
- BNAI 75.20
- BIAF 46.46
- Support Level
- BNAI $0.39
- BIAF $0.24
- Resistance Level
- BNAI $0.56
- BIAF $0.32
- Average True Range (ATR)
- BNAI 0.08
- BIAF 0.06
- MACD
- BNAI 0.03
- BIAF 0.01
- Stochastic Oscillator
- BNAI 64.58
- BIAF 28.07
About BNAI BRAND ENGAGEMENT NETWORK INC
Brand Engagement Network Inc is a generative AI (GenAI) company specializing in conversational AI solutions. Through its secure, human-like AI agents, available in different modalities, the company seeks to transform consumer engagement and elevate customer experience, productivity, and business performance.
About BIAF bioAffinity Technologies Inc.
bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company's product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer.